6 results about "Follicular fluid" patented technology

The application belongs to the technical field of biology and particularly relates to application of phosphatidylglycerol. The phosphatidylglycerol PG (20:4_22:6) is used as a biomarker, and through analysis on metabolites of follicular fluid, the application realizes diagnosis of decreased ovarian reserve (DOR) with high sensitivity, high specificity and high accuracy.

The utility model discloses a multifunctional cattle live ovum collection follicular fluid collecting tube relates to the technical field of veterinary medical instruments, including transparent tube, the outer wall of transparent tube is equipped with scale, the inner chamber fixed connection of transparent tube has the partition board, the top threaded connection of transparent tube has the pipe cover, the inside of pipe cover is provided with adjusting assembly, the inside of pipe cover is provided with positioning assembly. The utility model discloses through knob, transparent silica gel tube and positioning assembly cooperation, has reached the effect of real -time identification and accurate shunt, when observing that the transparent silica gel tube appears red blood, will knob rotate 120, drive transparent silica gel tube synchronous rotation, when rotating a certain distance, by positioning assembly to the positioning of fixed frame, the transparent silica gel tube aims at the matching chamber, so that the subsequent blood can be arranged into the matching chamber, avoids sample cross -contamination.

The invention relates to the technical field of livestock breeding biology, and discloses a method for promoting porcine ovary granular cell proliferation, which comprises the following steps: adding a porcine follicular fluid exosome into a porcine ovary granular cell culture system, and acting for a certain time at an effective concentration, so as to improve the proliferation activity of granular cells. After the exosome treatment, the apoptosis rate of granular cells can be reduced, the cell survival rate can be improved, and the granular cells can be promoted to secrete steroid hormones, including the estradiol level and the expression of progesterone synthetase. Cell experiments prove that the follicular fluid exosome can effectively improve the activity of granular cells, promote the process of a cell cycle, inhibit cell apoptosis and remarkably enhance the synthesis capacity of steroid hormones such as estradiol and progesterone, and a new intervention strategy is provided for improving follicular development and reproductive performance of sows.

Provided is technology for testing the likelihood of pregnancy and / or the likelihood of childbirth resulting from the pregnancy. Provided is a method of testing the likelihood of pregnancy from an egg that had been contained in a follicular fluid collected from a subject and / or the likelihood of childbirth resulting from the pregnancy, including step (1) of detecting at least one miRNA selected from (a) the group consisting of miR-16-2-3p, miR-378a-3p, miR-483-5p, miR-1246, and miR-1290, and / or from (b) the group consisting of miR-204-3p, miR-1468-5p, miR-424-5p, miR-30e-5p, miR-146a-5p, miR-202-5p, miR-370-3p, miR-506-3p, miR-3184-3p, miR-423-5p, miR-365a-5p, miR-514a-3p, miR-92b-5p, miR-27a-5p, miR-6873-3p, miR-451a, miR-122-5p, and miR-122b-3p, in a sample of the follicular fluid.

The application discloses application of follicular fluid exosome lncLIPE-AS1 in evaluation of embryo quality of patients with polycystic ovary syndrome and belongs to the field of assisted reproductive technology. The application finds that lncLIPE-AS1 is highly expressed in follicular fluid of patients with polycystic ovary syndrome, and finds that lncLIPE-AS1 is correlated with embryo quality and steroid hormone secretion of patients with polycystic ovary syndrome. Therefore, lncLIPE-AS1 can be used as a biomarker for evaluation of embryo development quality in the process of assisted reproduction of patients with polycystic ovary syndrome and prediction of success rate of assisted reproduction, and can also be used for screening of high-quality oocytes of patients with polycystic ovary syndrome and regulation of steroid hormone expression of patients with polycystic ovary syndrome.

The invention provides application of Jinfeng pills in preparation of a medicine for treating ovarian hyporesponsiveness. The Jinfeng pill provided by the invention can significantly improve the E2 and TT levels in serum and follicular fluid of a POR patient, and improve the mature ovum rate, the high-quality embryo rate, the clinical pregnancy rate and the living yield of the POR patient, thereby improving the IVF-ET treatment outcome of the POR patient.